Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Immunic Q3 2026 Results: Net Loss of $42.3M, Loss Widens

Immunic, Inc. reported a net loss of $109.0 million for the nine months ended September 30, 2026, compared to $77.9 million in the prior year, driven by increased research and development and general and administrative expenses. The company significantly strengthened its liquidity, ending the period with $132.0 million in cash following a $187.3 million private placement in February 2026.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-42.3-25.6
EPS (diluted, $ a share)$-0.99$-1.32

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: IMUX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Immunic, Inc.: key numbers

Share price
$7.23Close, Nov 16
Market cap
$115M
Shares outstanding
15.88MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Immunic, Inc.

All →
8:01 AM ET 8-K
Financial Results

Immunic Financial Results

Immunic, Inc. reported financial results for the third quarter of 2026 and provided a corporate update on its lead candidate, vidofludimus calcium. The company remains on track to report top-line data from its pivotal Phase 3 ENSURE trials in relapsing multiple sclerosis in December 2026, which could support a potential NDA submission.

Term
Q3 2026

“As we approach the top-line data from our Phase 3 ENSURE trials in relapsing multiple sclerosis (MS) in December, we believe Immunic is entering one of the most important periods in its history. We are evolving from a science-driven biotechnology company into a fully integrated commercial organization, with a key focus on understanding and addressing the needs of people living with MS.”

Erik Lundgren, Chief Executive Officer of Immunic

“Further, our Phase 3 ENSURE trials in relapsing MS continue to be on track to report top-line data in December 2026. Our teams remain focused on this readout and readiness for a potential NDA submission should the results be positive.”

Michael A. Panzara, M.D., M.P.H., Chief Medical Officer of Immunic
9:05 AM ET 8-K
Investor Presentation

Immunic Investor Presentation

Immunic, Inc. is hosting a Progressive Multiple Sclerosis (PMS) Research and Development Day webinar on November 5, 2026. The company filed a formal investor presentation deck (Exhibit 99.1) to be used during the event, covering its development programs and clinical data for vidofludimus calcium.

9:09 AM ET 8-K
Leadership Change

Immunic Leadership Change

Dr. Duane Nash resigned from the Board of Directors of Immunic, Inc. on September 10, 2026. Following the resignation, the company reduced the size of its Board from ten to nine members.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.